Breaking News

Tweet TWEET

Illumina Launches TruSight™ Tumor Content Set

  Illumina Launches TruSight™ Tumor Content Set

   Enables Somatic Variant Detection in Solid Tumors Using Next-Generation
                               Sequencing (NGS)

Business Wire

SAN DIEGO -- April 4, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced the next product in its TruSight
line of content sets, TruSight Tumor, for NGS-based somatic variant detection
in solid tumors. TruSight Tumor provides optimized amplicon-based library
preparation of 26 oncogenes and tumor suppressor genes selected for their
involvement in common solid tumors, including lung, colon, melanoma, gastric,
and ovarian cancer.

TruSight Tumor also offers a comprehensive NGS-based tumor profiling solution
that provides a broader and more cost-effective view of tumor heterogeneity
compared to genotyping-based methods. Researchers can simultaneously detect
somatic changes in multiple genes across the tumor genome, as referenced in
industry guidelines, as well as emerging biomarkers implicated in
pharmaceutical clinical trials. Designed for use with formalin-fixed
paraffin-embedded (FFPE) samples, TruSight Tumor enables high levels of
sensitivity for minor allele detection (below 5%), with limited DNA input
requirements.

“TruSight Tumor is designed to run on Illumina’s industry-leading sequencing
platforms and enables clinical researchers to understand the molecular
heterogeneity of FFPE tumor samples,” said Matt Posard, Senior Vice President
and General Manager of Illumina’s Translational and Consumer Genomics
business. “This technology has the potential to expand candidates for targeted
therapies who may otherwise be missed with single variant or single gene
approaches.”

“Tumor characterization using next-generation sequencing enables clinical
research laboratories to gain a deeper understanding of underlying biology. In
order to detect clinically relevant variants, it is important to look beyond
single genes or hotspot mutations while achieving very low levels of
sensitivity,"said Dr. Robert Daber, Technical Director of Clinical Genomics,
Center for Personalized Diagnostics, Department of Pathology and Laboratory
Medicine, Perelman School of Medicine, University of Pennsylvania.

TruSight Tumor is the first content set designed for somatic variant detection
on the Illumina MiSeq® platform. As a portfolio, TruSight content sets are
designed for high performance targeted sequencing to meet the specific needs
of the clinical research laboratory by providing high analytical sensitivity
and specificity. They offer exceptional performance in the capture and
sequencing of targeted genomic regions, and are selected through
collaborations with experts from leading institutions.

TruSight content sets are for research use only and not intended for
diagnostic use. TruSight Tumor is now available for order with shipment
expected in Q2’13. For more information, visit www.illumina.com/TruSightTumor.

About Illumina

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and
marketer of life science tools and integrated systems for the analysis of
genetic variation and function. We provide innovative sequencing and
array-based solutions for genotyping, copy number variation analysis,
methylation studies, gene expression profiling, and low-multiplex analysis of
DNA, RNA, and protein. We also provide tools and services that are fueling
advances in consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way for
molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected shipping date for
TruSight Tumor. Important factors that could cause actual results to differ
materially from those in any forward-looking statements include challenges
inherent in developing, manufacturing, and launching new products and services
and the other factors that are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms 10-K and 10-Q,
or in information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any forward-looking
statements after the date of this release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.